L-Glutamic γ-monohydroxamate

L-Glutamic γ-monohydroxamate is an antitumor agent, inhibits cell proliferation. L-Glutamic γ-monohydroxamate selectively inhibits the uptake of L-histidine into microvascular endothelial cell. L-Glutamic γ-monohydroxamate, as a vanadium ligand, activates glucose uptake and metabolism, thus decreases the blood glucose levels in vivo[1][2][3].

Product Specifications

CAS Number

[1955-67-5]

UNSPSC

12352209

Hazard Statement

H302, H315, H319, H335

Target

Others

Type

Peptides

Related Pathways

Others

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Cancer; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/l-glutamic-γ-monohydroxamate.html

Purity

99.66

Solubility

H2O : 83.33 mg/mL (ultrasonic)

Smiles

N[C@H](C(O)=O)CCC(NO)=O

Molecular Formula

C5H10N2O4

Molecular Weight

162.14

Precautions

H302, H315, H319, H335

References & Citations

[1]Vila J, et al. In vitro and in vivo anti-tumor activity of L-glutamic acid gamma-monohydroxamate against L1210 leukemia and B16 melanoma. Int J Cancer. 1990 Apr 15;45 (4) :737-43.|[2]Sakurai E, et al. Stereoselective transport of histidine in rat lung microvascular endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2002 Jun;282 (6) :L1192-7.|[3]Goldwaser I, et al. L-Glutamic acid gamma-monohydroxamate. A potentiator of vanadium-evoked glucose metabolism in vitro and in vivo. J Biol Chem. 1999 Sep 10;274 (37) :26617-24.